Navigation Links
Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
Date:5/17/2012

SAN DIEGO, May 17, 2012 /PRNewswire/ -- Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120 (AAV2-neurturin).  Raymond T. Bartus, Ph.D., Ceregene's chief scientific officer and executive vice president, was invited to give a presentation entitled "The Development of AAV2-neurturin (CERE-120) for Parkinson's Disease: A Review of the Challenges and Translation Issues Confronted During the Course of Establishing 'Clinical Proof of Concept,'" at the annual meeting of the American Society for Gene and Cell Therapy during the Clinical Trials I Symposium on Thursday, May 17, 2012 in Philadelphia, PA.  CERE-120 is a viral vector engineered to deliver the nervous system growth factor neurturin (NRTN), which has the ability to rejuvenate degenerating dopamine-producing neurons, restoring function and keeping them alive.  NRTN has been shown to safely protect and restore damaged nigrostriatal nerves in animal models of Parkinson's disease and appears safe in humans tested in four Ceregene-sponsored clinical studies enrolling a total of 120 patients, 80 of whom were administered CERE-120.  A previous double blind-controlled human study demonstrated clinical benefit on several motor and Quality of Life (QOL) endpoints 12 and 18 months following CERE-120 delivery (with no measure favoring sham) and established clinical proof of concept in humans. 

Dr. Bartus will present histological evaluation of autopsy tissue from subjects administered CERE-120 to the brain who later died of unrelated causes.  Analysis of brains from Parkinson's subjects 1.5 and 3 months post-CERE-120 treatment revealed NRTN expression in the targeted putaminal regio
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
2. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
3. Ceregene Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinsons Disease
4. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
7. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014  Relmada ... therapies for the treatment of chronic pain, announced today ... Sloan Kettering Cancer Center (MSKCC) in a series of ... ER, a new tamper-resistant, extended release form of levorphanol. ... investigator for these studies. Dr. Pasternak ...
(Date:9/15/2014)... NEW YORK , Sept. 16, 2014 ... Neuropathy Foundation (HNF) announced today an agreement to collaborate ... disease and support the development of a stronger CMT ... provide financial support to several HNF,s initiatives including: ... section in the HNF website featuring  HNF newsletters, materials ...
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics ... specialty pharmaceutical company with a focus on Omega-3 ... today that the Board of Directors approved the ... an advisor at the close of business on Friday, ... of 1,000,000 common shares of the Company were ...
Breaking Medicine Technology:Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Pivotal Therapeutics Grants Incentive Stock Options 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 2FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 3FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 4FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 5FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 6FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 7FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 8FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 9FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 10FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 11Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 2Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 3Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 4Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 5Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review 6
(Date:9/16/2014)... September 16, 2014 Wholelifeinsurancecompanies.org has released ... find life insurance with a bad heart condition. , ... find affordable life insurance if they compare quotes. Most ... the decision depend on the actual and past medical ... that caused several heart attacks in the past, his ...
(Date:9/16/2014)... positron emission tomography (PET) tracer is effective in diagnosing ... according to a case study conducted at the Icahn ... Neuroimaging (MNI) LLC in New Haven, and published September ... Specifically, the study results suggest that an experimental radiolabeled ... onto a protein called tau that accumulates in the ...
(Date:9/16/2014)... soon better predict a man,s risk of getting prostate ... the largest-ever analysis of the cancer,s genetic biomarkers, reported ... of Health and Biomedical Innovation,s Dr Jyotsna Batra and ... in the large consortia of research hubs around the ... genetic markers in 80,000 men. , "It,s the largest ...
(Date:9/16/2014)... York, NY (PRWEB) September 16, 2014 ... in diagnosing concussion-related brain disease while a person is ... the Icahn School of Medicine at Mount Sinai, and ... published September 16 in the journal Translational Psychiatry. , ... compound called [18 F]-T807, which is designed to latch ...
(Date:9/16/2014)... 16, 2014 The Muscular Dystrophy ... flu vaccines for individuals affected by muscle disease, ... other neuromuscular diseases. , MDA offers this service ... disease who, because of compromised respiratory function — ... lungs — are at increased risk of serious ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4Health News:MDA Offers Flu Shots to Those Affected by Muscle Disease 2
... and vegetable juice could stave off Alzheimer's disease, say ... in the skin and peels of fruits and vegetables. ... ,Lab trials have earlier shown that polyphenols can ... to significantly delay the onset of serious cognitive impairment. ...
... silent killer worldwide and it is imperative to make people aware ... to be taken, say medical experts.// ,Now in its third ... to increase awareness about hepatitis B and C. The theme for ... silent disease. Most of the people are unaware that they have ...
... economic, social and health factors affecting African Americans, Penn ... Black’//. , ,Dr. Shaun Gabbidon, associate professor of ... and public policy, both at Penn State's Harrisburg campus, ... the Journal of Black Studies. , ,"There are ...
... among eighty countries has found that the Iraqi public portrays ... // out-groups. Ethnic solidarity seems to be at an all ... on restoration of order and security, along with emergence of ... embittered and torn Iraqi nation. The analysis is an outcome ...
... starches and sugars with unhealthy high-fat foods? A new ... ,A recent study of an internet-based support ... for dieters on low-carbohydrate diets has been the addition ... carbohydrates removed from their diet. The report was published ...
... antibiotic shows early promise as an anti-cancer agent, inhibiting ... tumors, // according to researchers at the University of ... appear in the Oct. 1 issue of Cancer Research. ... to be over-expressed in cancer cells to screen for ...
Cached Medicine News:Health News:Awareness Must to Tackle Hepatitis: Experts 2Health News:Understanding Stress Triggers for African Americans 2Health News:Iraqi’s Gripped with Insecurit 2Health News:Iraqi’s Gripped with Insecurit 3Health News:Low-Carb Dieters Eat More Vegetables 2Health News:Antibiotic Inhibits Cancer Gene Activity 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: